Operating cost

Kura Sushi USA Announces Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Jeudi, avril 4, 2024
Comparable, Interest, Telephone, Webcast, SVP, Travel, Operating cost, Public expenditure, Kura Sushi, Adjustment, Advertising, Restaurant, DoorDash, Total, Food, Video game

IRVINE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”) (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced financial results for the fiscal second quarter ended February 29, 2024.

Key Points: 
  • IRVINE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”) (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced financial results for the fiscal second quarter ended February 29, 2024.
  • Total sales were $57.3 million, compared to $43.9 million in the second quarter of 2023;
    Comparable restaurant sales increased 3.0% for the second quarter of 2024 as compared to the second quarter of 2023;
    Operating loss was $1.7 million, compared to operating loss of $1.0 million in the second quarter of 2023;
    Net loss was $1.0 million, or $(0.09) per diluted share, compared to net loss of $1.0 million, or $(0.10) per diluted share, in the second quarter of 2023;
    Restaurant-level operating profit* was $11.2 million, or 19.6% of sales;
    Adjusted EBITDA* was $2.9 million; and
    Five new restaurants opened during the fiscal second quarter of 2024.
  • Comparable restaurant sales increased 3.0% for the second quarter of 2024 as compared to the second quarter of 2023.
  • During the fiscal second quarter of 2024, the Company opened five new restaurants in Kansas City, Missouri; Skokie, Illinois; Columbus, Ohio; Euless, Texas; and Webster, Texas.

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Retrieved on: 
Mercredi, avril 3, 2024
Research, Transcoding, Brain, Survival, CFO, TTX, Patient, Operating cost, RNA, Sale, CMC, Cancer, OTS, IND, AACR, Glioblastoma, Pancreatic cancer, Therapy, Genomics, CRISPR, Breast cancer, Melanoma, Debiopharm, FDA, Liver, IRB, Pharmaceutical industry

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.

Key Points: 
  • BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.
  • “We believe 2023 was extremely productive and pivotal for TransCode.
  • The year was highlighted by preliminary clinical results from our Phase 0 clinical trial with radiolabeled TTX-MC138,” said Tom Fitzgerald, interim CEO and CFO of TransCode.
  • We also continued to achieve other important milestones, with the ultimate objective of fulfilling the promise of RNA therapeutics for oncology applications.

DIGITAL ALLY, INC ANNOUNCES 2023 OPERATING RESULTS

Retrieved on: 
Mardi, avril 2, 2024
Agreement, Social media, Health care, Sale, Business analyst, Closing, Note, Marketing, Moshing, Form, Heartland Stampede Music Festival, Prospectus, George M. Steinbrenner Field, Kustom, Plan, Country, News, Acquisition, Senior, Suite, Security, Brickell Avenue, Security agreement, Operating cost, EDT, Sub, The Borrowers, Finance Secretary (India), Traction, Music, ID, Patent, DGLY, Cryptocurrency

LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.

Key Points: 
  • LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.
  • Operating losses for the year ended December 31, 2023 and 2022 were $22,240,553 and $29,733,258, respectively, a decrease of $7,492,705 (25%).
  • Operating loss as a percentage of revenues improved to 78% in 2023 from 80% in 2022.
  • The Company will host an investor conference call at 11:15 a.m. EDT on Tuesday, April 2, 2023, to discuss its 2023 financial results, corporate and individual subsidiary outlook, and previously announced corporate separation.

Airship AI Reports Full Year 2023 Financial Results

Retrieved on: 
Lundi, avril 1, 2024
Cloud, Theft, Health, Federation, Organization, Government, Growth, Intelligence, DHS, Internet of things, Public company, Operating cost, Social media, Law enforcement, Acquisition, Outpost, United, DOJ, Nvidia, Workflow, Safety, FedRAMP, Workplace, Data management, Acropolis

REDMOND, Wash., April 01, 2024 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today reported its financial and operational results for the full year ended December 31, 2023.

Key Points: 
  • Business combination strategically positions Airship AI, a robust AI-driven video, sensor and data management surveillance platform for government agencies and enterprises, to accelerate growth and revenue.
  • Gross margin percentage was 47% for the year ended December 31, 2023, primarily due to a higher percentage of third-party hardware sales as part of turn-key solution bundled by Airship AI with Outpost AI included.
  • Multiple new Airship AI trained AI models released supporting advanced AI processing at the edge.
  • “The fourth quarter of 2023 was highlighted by our Nasdaq listing in late December,” said Paul Allen, President of Airship AI.

Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023

Retrieved on: 
Lundi, avril 1, 2024
Growth, MLSS, Webcast, Telephone, Education, Dental Service Organizations, Operating cost, Hospital, United, CPT, Injection, Pain management, STA, Physician

Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.

Key Points: 
  • Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.
  • For the year ended December 31, 2023, international revenue was approximately $4.1 million, a decrease of $724,000 compared to December 31, 2022.
  • Gross profit for the year ended December 31, 2023, was $6.8 million versus $4.9 million for the year ended December 31, 2022.
  • Operating loss for the year ended December 31, 2023, was $7.1 million versus $8.8 million for the year ended December 31, 2022.

XBP Europe Holdings, Inc. Reports Full Year 2023 Results

Retrieved on: 
Lundi, avril 1, 2024
Capital expenditure, Growth, TCV, Bill, Operating cost, Sale, XBP, Adjustment, Bookkeeping

LONDON and SANTA MONICA, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- XBP Europe Holdings, Inc. (“XBP” or the “Company”) (NASDAQ: XBP), a pan-European integrator of bills and payments and related solutions and services seeking to enable the digital transformation of its clients, announced today its financial results for the full year ended December 31, 2023.

Key Points: 
  • “We start the year as a newly listed public company, having completed our long-awaited business combination towards the very end of 2023.
  • We will keep our employees and the investor community apprised of our progress in the coming weeks and months,” said Andrej Jonovic, Chief Executive Officer of XBP.
  • Net Loss: Net loss for 2023 was $11.0 million, compared with a net loss of $7.9 million in 2022.
  • Adjusted EBITDA(1): Adjusted EBITDA for 2023 was $11.6 million, a decrease of 20.0% compared to $14.5 million in 2022.

Reed’s Reports Fourth Quarter and Full Year 2023 Results and Issues 2024 Financial Outlook

Retrieved on: 
Jeudi, mars 28, 2024
SAFE, Insurance, Operating cost, Growth, Policy, OTCQX, Pharmaceutical industry

NORWALK, Conn., March 28, 2024 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three and twelve months ended December 31, 2023.

Key Points: 
  • FY 2023 Financial Highlights (vs. FY 2022):
    Net sales were $44.7 million compared to $53.0 million.
  • Delivery and handling costs were reduced by 32% to $1.8 million during the fourth quarter of 2023 compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general and administrative costs declined by 23% to $3.0 million during the fourth quarter of 2023 compared to $3.9 million in the year-ago quarter.
  • Modified EBITDA improved to $43,000 in the fourth quarter of 2023 compared to $(2.8) million in the fourth quarter of 2022.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Jeudi, mars 28, 2024
Research, HCPCS, Gait, Patient, Operating cost, Stroke, Sale, Acquisition, HSDT, Andreyev, Social services, ATM, Pons, Medicare, FDA, CMS, PTAP, Food, Video game

NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Gross profit for the fourth quarter of 2023 was $44 thousand, compared to gross profit of $132 thousand in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 decreased to a loss of $2.2 million, compared to an operating loss of $2.7 million in the fourth quarter of 2022.
  • Net loss was $1.0 million for the fourth quarter of 2023, compared to a net loss of $4.9 million in the fourth quarter of 2022.
  • The basic and diluted net loss per share for the fourth quarter 2023 was $1.47, compared to net loss per share of $8.66 in the fourth quarter 2022.

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Mercredi, mars 27, 2024
AAGL, Patient, TMS, Investment, Endometriosis, Therapy, USD, Marketing, Congress, Urology, Teaching hospital, INPI, Food, Prostate cancer, EAU, Cancer, Hospital, Intellectual property, AUA, FDA, Diagnosis, DIE, Growth, EDAP, Operating cost, EDT, Randomized controlled trial

Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.

Key Points: 
  • Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.
  • The increase was driven by 10 Focal One systems sold in the fourth quarter of 2023 versus 7 systems sold in the fourth quarter of 2022.
  • Total revenue in the Distribution business for the fourth quarter of 2023 was EUR 9.9 million (USD 10.7 million), as compared to EUR 6.7 million (USD 7.0 million) for the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was EUR 3.5 million (USD 3.8 million), compared to an operating loss of EUR 1.6 million (USD 1.6 million) in the fourth quarter of 2022.

Actelis Networks Reports Fiscal Full Year 2023 Results

Retrieved on: 
Mardi, mars 26, 2024
UL, Research, ASNS, Department of Defence, Certification, Temperature, Development, Interoperability, Partnership, Operating cost, City, IPO, Bret Harrison, Senior, Marketing, NIST, Investment, FIPS, Public sector, Airport, MDU, Cryptocurrency

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, hybrid-fiber rapid deployment networking solutions for wide area IoT applications, today reported financial results for the fiscal full year 2023 ended December 31, 2023.

Key Points: 
  • FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, hybrid-fiber rapid deployment networking solutions for wide area IoT applications, today reported financial results for the fiscal full year 2023 ended December 31, 2023.
  • Direct margin increase: Gross Margin was 34% for the full year 2023, compared to 47% in the prior year.
  • Substantial improvement in operating expenses: Operating expenses declined by 9% to $9.3 million for the full year 2023.
  • Fiscal Full Year 2023 Financial Highlights:
    Revenues for the year ended December 31, 2023 amounted to $5.6 million, compared to $8.8 million for the year ended December 31, 2022.